Antengene Valuation
Is 722 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 722 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 722's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 722's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 722?
Key metric: As 722 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 722's PS Ratio? | |
|---|---|
| PS Ratio | 7.6x |
| Sales | CN¥56.07m |
| Market Cap | CN¥423.49m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 722's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.1x | ||
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
HIGH Cantourage Group | 29.5x | 38.6% | €57.9m |
2FJ0 Pierrel | 3.4x | n/a | €92.8m |
APPH Apontis Pharma | 2x | 17.3% | €81.1m |
722 Antengene | 7.6x | 66.1% | €455.2m |
Price-To-Sales vs Peers: 722 is good value based on its Price-To-Sales Ratio (7.6x) compared to the peer average (12x).
Price to Sales Ratio vs Industry
How does 722's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 24 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 24 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 722 is expensive based on its Price-To-Sales Ratio (7.6x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is 722's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 7.6x |
| Fair PS Ratio | 20.3x |
Price-To-Sales vs Fair Ratio: 722 is good value based on its Price-To-Sales Ratio (7.6x) compared to the estimated Fair Price-To-Sales Ratio (20.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.052 | €0.20 +274.3% | 5.3% | €0.21 | €0.19 | n/a | 2 |
| Nov ’25 | €0.07 | €0.20 +180.7% | 5.3% | €0.21 | €0.19 | n/a | 2 |
| Oct ’25 | €0.06 | €0.20 +227.5% | 5.3% | €0.21 | €0.19 | n/a | 2 |
| Sep ’25 | €0.044 | €0.19 +340.9% | 4.3% | €0.20 | €0.19 | n/a | 2 |
| Aug ’25 | €0.035 | €0.21 +504.2% | 11.9% | €0.24 | €0.19 | n/a | 2 |
| Jul ’25 | €0.063 | €0.21 +238.5% | 11.5% | €0.24 | €0.19 | n/a | 2 |
| Jun ’25 | €0.093 | €0.21 +128.1% | 11.5% | €0.24 | €0.19 | n/a | 2 |
| May ’25 | €0.095 | €0.21 +124.5% | 11.5% | €0.24 | €0.19 | n/a | 2 |
| Apr ’25 | €0.096 | €0.21 +122.1% | 11.5% | €0.24 | €0.19 | n/a | 2 |
| Mar ’25 | €0.12 | €0.50 +315.4% | 48.0% | €0.74 | €0.26 | n/a | 2 |
| Feb ’25 | €0.13 | €0.50 +292.5% | 48.0% | €0.74 | €0.26 | n/a | 2 |
| Jan ’25 | €0.21 | €0.51 +149.9% | 43.7% | €0.74 | €0.29 | n/a | 2 |
| Dec ’24 | €0.23 | €0.51 +127.8% | 43.7% | €0.74 | €0.29 | n/a | 2 |
| Nov ’24 | €0.16 | €0.54 +231.2% | 34.6% | €0.74 | €0.29 | €0.07 | 3 |
| Oct ’24 | €0.13 | €0.54 +331.1% | 34.6% | €0.74 | €0.29 | €0.06 | 3 |
| Sep ’24 | €0.12 | €0.66 +434.9% | 8.2% | €0.73 | €0.60 | €0.044 | 3 |
| Aug ’24 | €0.15 | €0.74 +383.7% | 18.6% | €0.93 | €0.60 | €0.035 | 3 |
| Jul ’24 | €0.16 | €0.80 +401.1% | 17.7% | €0.96 | €0.63 | €0.063 | 4 |
| Jun ’24 | €0.20 | €0.80 +300.9% | 17.7% | €0.96 | €0.63 | €0.093 | 4 |
| May ’24 | €0.28 | €0.80 +190.5% | 17.7% | €0.96 | €0.63 | €0.095 | 4 |
| Apr ’24 | €0.30 | €0.87 +190.8% | 13.4% | €0.97 | €0.71 | €0.096 | 3 |
| Mar ’24 | €0.46 | €1.19 +155.4% | 38.2% | €1.81 | €0.76 | €0.12 | 3 |
| Feb ’24 | €0.62 | €1.20 +93.7% | 40.1% | €1.87 | €0.75 | €0.13 | 3 |
| Jan ’24 | €0.60 | €1.20 +100.2% | 40.1% | €1.87 | €0.75 | €0.21 | 3 |
| Dec ’23 | €0.47 | €1.30 +176.8% | 42.6% | €1.85 | €0.75 | €0.23 | 2 |
| Nov ’23 | €0.41 | €1.35 +225.0% | 42.5% | €1.92 | €0.77 | €0.16 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.9b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$15.55
7D
1.6%
1Y
73.9%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.45
7D
1.1%
1Y
2.9%